The European Patent Office (EPO) has officially granted patent EP2837680B1, related to mammalian cell culture technologies, with an effective grant date of March 18, 2026. This patent, which lists specific inventors and includes various International Patent Classification (IPC) codes such as C12P 21/02 and C12N 5/00, covers a range of designated states within Europe.

This grant represents the formal recognition of intellectual property rights for the inventors and their associated entities. While this is a grant of a patent and not a regulatory rule imposing new compliance obligations, entities operating in the biotechnology and pharmaceutical sectors, particularly those involved in cell culture research and development, should be aware of this granted patent. It may impact their freedom to operate or necessitate licensing agreements if their activities fall within the scope of the patent claims.